Verastem (VSTM) Shares Soar 2.65% on Jefferies Buy Rating
Mover TrackerFriday, Apr 11, 2025 6:25 pm ET

Verastem (VSTM) shares surged 2.65% today, marking a significant rebound after hitting its lowest level since December 2024, with an intraday decline of 3.98%.
Verastem's stock price has been positively influenced by Jefferies initiating a Buy rating with a target price of $15. This rating is primarily due to the potential FDA approval for its ovarian cancer drug combination. The FDA action date is set for June 30, which could further impact the stock depending on the outcome. This news has generated optimism among investors, who are closely monitoring the regulatory process for the drug combination.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet